http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109251937-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66 |
filingDate | 2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-109251937-B |
titleOfInvention | Construction method and application of human-Sin 3 related polypeptide P18 overexpression plasmid |
abstract | The invention discloses a construction method and application of a human-Sin 3 related polypeptide P18(SAP18) overexpression plasmid. The method comprises the following steps: as shown in SEQ ID No: 2-3 as a primer, and taking a sequence of GenBank accession number NC-10284 as a template to carry out PCR amplification to obtain a target gene; and (3) carrying out enzyme digestion, purification and connection on the PCR product and the pCDH-CMV-MCS-EF 1-copRPF vector by using restriction endonucleases XbaI and Not I, and transforming to escherichia coli to obtain an overexpression plasmid. The obtained human-Sin 3 related polypeptide P18 is applied to the preparation of products for preventing or treating Kaposi's sarcoma. The invention discloses SAP18 over-expressing endothelial cells, which can obviously inhibit the migration, invasion and angiogenesis of the endothelial cells, and SAP18 can be used as a new molecular marker and a drug target of KS diagnosis and treatment. |
priorityDate | 2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.